Ziccum
Interim Report
Q2 2021
Ziccum in short
Ziccum's patented technology LaminarPace air-dries liquid vaccine into a thermostable powder vaccine. Before it is administered, the vaccine powder is mixed with liquid and can then be injected in exactly the same way as a liquid solution vaccine.
The LaminarPace technology is gentle, air-drying takes place at room temperature, resulting in powder vaccines becoming thermostable. This means that the vaccine can be transported and stored at room temperature, unlike today's vaccines that require costly, complex logistics with an unbroken freeze or cold chain.
19 %
Increase in the number of children who have had their national vaccination program interrupted due to the Covid-19 pandemic
7 %
of global greenhouse gas emissions come from cooling, such as cold chains, industrial processes, and the air conditioning of buildings
32 %
of the world's inhabitants have received at least one vaccine dose against COVID-19
1 %
of inhabitants in low-income countries have received at least one vaccine dose against COVID-19
Vision
Ziccum's vision is to increase vaccination coverage worldwide, so contributing to a more equal distribution of vaccines. We can do this by both increasing the regional production of vaccines, and simplifying how we distribute them, minimizing our dependence on expensive, energy-intensive cold and freezer chains.
The need for vaccine has never been greater than it is today
Vaccination is and has always been one of the best ways to prevent pandemics and epidemics. The need has never been greater than it is today. Not least due to the Covid-19 pandemic, which has proven the enormous benefits vaccines have on society as whole. Increasing global travel, population growth, climate change, urbanization and overcrowding are all potential risks for starting new epidemics and pandemics. And it is children who are exposed most; one out of five still don’t have adequate vaccine coverage. About1.5 million children die every year of vaccine-preventable diseases. Adults too have been hit hard by the Covid-19 pandemic, and many countries have realized the value of having their own vaccine production facilities.
NO ONE IS SAFE UNTIL EVERYONE IS SAFE
The global challenges facing the vaccine industry have become impossible to ignore. The development of new vaccines has been fast and impressive - but the lack of regional production capacity and global logistics problems remain. Establishing agile, small-scale production facilities regionally, each equipped with Ziccum's patented LaminarPace technology manufacturing thermostable powder vaccines – can be a major solution – making sure more vaccines reach more people, for the security of us all.